{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T14:04:02Z","timestamp":1785074642226,"version":"3.55.0"},"reference-count":232,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Inorganic Biochemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jinorgbio.2026.113397","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:19:12Z","timestamp":1782343152000},"page":"113397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From PET to targeted radionuclide therapy in the Brain: The emerging role of radiometal-based platforms"],"prefix":"10.1016","volume":"283","author":[{"given":"Jacqueline","family":"Cawthray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinorgbio.2026.113397_bb0005","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/S2468-2667(25)00089-1","article-title":"Estimating global direct health-care spending on neurological and mental health between 2000 and 2019: a modelling study","volume":"10","author":"Mitchell","year":"2025","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0010","article-title":"The global, regional, and national brain and central nervous system cancer burden and trends from 1990 to 2021: an analysis based on the Global Burden of Disease Study 2021","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0015","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0020","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011\u20132015","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","article-title":"Glioblastoma at the crossroads: current understanding and future therapeutic horizons","volume":"10","author":"Singh","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0030","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0035","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/neuonc\/nox112","article-title":"PET imaging in patients with meningioma\u2014report of the RANO\/PET Group","volume":"19","author":"Galldiks","year":"2017","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0040","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3390\/ijms26052307","article-title":"Molecular underpinnings of brain metastases","volume":"26","author":"Jacome","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s43556-025-00251-0","article-title":"Cancer brain metastasis: molecular mechanisms and therapeutic strategies","volume":"6","author":"Lu","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0050","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/jmri.70046","article-title":"Clinical translation of integrated PET-MRI for neurodegenerative disease","volume":"63","author":"Shepherd","year":"2026","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0055","series-title":"Challenges, Limitations, and Pitfalls of PET and Advanced MRI in Patients with Brain Tumors: A Report of the PET\/RANO Group","author":"Galldiks","year":"2026"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0060","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/molecules25030568","article-title":"Approaches to PET imaging of glioblastoma","volume":"25","author":"Drake","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0065","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.7150\/thno.56639","article-title":"A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma","volume":"11","author":"Bolcaen","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0070","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/cancers14051103","article-title":"PET imaging in neuro-oncology: an update and overview of a rapidly growing area","volume":"14","author":"Verger","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0075","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/RLU.0b013e3181becfe0","article-title":"Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET\/CT for metabolic imaging of low grade gliomas","volume":"34","author":"Tripathi","year":"2009","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0080","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/neuonc\/noz003","article-title":"PET imaging in patients with brain metastasis\u2014report of the RANO\/PET group","volume":"21","author":"Galldiks","year":"2019","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0085","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2967\/jnumed.123.266463","article-title":"Evaluation of neurodegenerative disorders with Amyloid-\u03b2, Tau, and dopaminergic PET imaging: interpretation pitfalls","volume":"65","author":"Burkett","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1549676","article-title":"An overview of current phase 3 radiopharmaceutical therapy clinical trials","volume":"12","author":"Lepareur","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0100","article-title":"Spatial resolution and image quality of radionuclides for PET imaging","volume":"154\u2013155","author":"Samuel","year":"2026","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0105","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adp2840","article-title":"Positronium image of the human brain in vivo","volume":"10","author":"Moskal","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.zemedi.2026.03.004","article-title":"First ex-vivo positronium imaging of tissues with modular J-PET scanner using 44Sc radionuclide","author":"Kubat","year":"2026","journal-title":"Z F\u00fcr Med. Phys."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0020-708X(60)90052-1","article-title":"A positron cow","volume":"8","author":"Gleason","year":"1960","journal-title":"Int. J. Appl. Radiat. Isot."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.apradiso.2012.10.012","article-title":"Past, present and future of 68Ge\/68Ga generators","volume":"76","author":"R\u00f6sch","year":"2013","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0125","article-title":"Production and purification of radiolabeling-ready 132\/135La from the irradiation of metallic natBa targets with low energy protons","volume":"144\u2013145","author":"Kurakina","year":"2025","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0130","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.2967\/jnumed.120.255794","article-title":"Cyclotron-produced 132La as a PET imaging surrogate for therapeutic 225Ac","volume":"62","author":"Aluicio-Sarduy","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0135","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1039\/C9SC04655K","article-title":"Chelation with a twist: a bifunctional chelator to enable room temperature radiolabeling and targeted PET imaging with scandium-44","volume":"11","author":"Vaughn","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0140","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.nucmedbio.2020.05.005","article-title":"Review on 99mTc radiopharmaceuticals with emphasis on new advancements","volume":"92","author":"Duatti","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2022.214911","article-title":"Technetium(I) carbonyl complexes for nuclear medicine: coordination-chemical aspect","volume":"476","author":"Sidorenko","year":"2023","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0150","article-title":"Quantitative comparison of SPECT and PET performance for clinical theranostic applications","author":"Salerno","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0155","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2967\/jnumed.123.267189","article-title":"First-in-Human 212Pb-PSMA\u2013Targeted \u03b1-therapy SPECT\/CT imaging in a patient with metastatic castration-resistant prostate cancer","volume":"65","author":"Griffiths","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0160","author":"National Nuclear Data Center"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0165","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching chelators to radiometals for radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0170","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1021\/acs.molpharmaceut.5c01955","article-title":"Rational selection of chelators for theranostic radionuclides: insights from Ab initio computational modeling","volume":"23","author":"Kim","year":"2026","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0175","article-title":"Radiometal-based PET imaging: coordination chemistry as a determinant of in vivo performance","author":"Liu","year":"2026","journal-title":"Eur. J. Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0180","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1021\/cr00098a011","article-title":"Ligand design for selective complexation of metal ions in aqueous solution","volume":"89","author":"Hancock","year":"1989","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0185","doi-asserted-by":"crossref","DOI":"10.1021\/acs.chemrev.5c00641","article-title":"Chemical tools to characterize the coordination chemistry of radionuclides for radiopharmaceutical applications","author":"Boros","year":"2025","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0190","doi-asserted-by":"crossref","first-page":"9769","DOI":"10.1021\/acs.inorgchem.5c05424","article-title":"Macropa scaffold expansion for actinium-225 chelation: a synthetic strategy, labeling kinetics, and theoretical calculations","volume":"65","author":"Baier","year":"2026","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0195","doi-asserted-by":"crossref","first-page":"6836","DOI":"10.1021\/acs.inorgchem.6c00216","article-title":"Challenging the macrocycle paradigm: four-arm, high-denticity acyclic chelators for radiopharmaceuticals incorporating actinium and lanthanides","volume":"65","author":"Fern\u00e1ndez-Pav\u00f3n","year":"2026","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0200","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1039\/c3cc41554f","article-title":"Tumour targeting with radiometals for diagnosis and therapy","volume":"49","author":"Ramogida","year":"2013","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0205","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s00259-025-07619-y","article-title":"Prospective pilot study with [89Zr]Zr-girentuximab PET\/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE)","volume":"53","author":"Rousseau","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0210","article-title":"Investigating the fate of Zirconium-89 labelled antibody in cynomolgus macaques","volume":"144\u2013145","author":"Sasaki","year":"2025","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0215","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.3390\/pharmaceutics14102114","article-title":"Toward optimized 89Zr-Immuno-PET: side-by-side comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for tumor imaging: which chelator is the most suitable?","volume":"14","author":"Damerow","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0220","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.nucmedbio.2010.12.011","article-title":"In vivo biodistribution and accumulation of 89Zr in mice","volume":"38","author":"Abou","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0225","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00259-016-3499-x","article-title":"Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET","volume":"44","author":"Vugts","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0230","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00259-020-05002-7","article-title":"Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET","volume":"48","author":"Chomet","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0235","doi-asserted-by":"crossref","first-page":"20964","DOI":"10.1021\/acs.inorgchem.2c03442","article-title":"Design, synthesis, and evaluation of DFO-Em: A modular chelator with octadentate chelation for optimal zirconium-89 radiochemistry","volume":"61","author":"Salih","year":"2022","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0240","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1021\/jm500389b","article-title":"Alternative chelator for 89Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO)","volume":"57","author":"Deri","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0245","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.3390\/cancers13174466","article-title":"The race for hydroxamate-based zirconium-89 chelators","volume":"13","author":"Feiner","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2025.113077","article-title":"Synthesis and evaluation of HOPO-O8-Methyl-tetrazine as a bifunctional chelator for use in [89Zr]Zr4+, [161Tb]Tb3+ and [227Th]Th4+ radioimmunoconjugates","volume":"274","author":"Carbo-Bague","year":"2026","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0255","doi-asserted-by":"crossref","DOI":"10.1021\/ja106399h","article-title":"Acyclic chelate with ideal properties for 68Ga PET imaging agent elaboration","volume":"132","author":"Boros","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0260","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1021\/acs.bioconjchem.9b00225","article-title":"Functionally versatile and highly stable chelator for 111In and 177Lu: Proof-of-principle prostate-specific membrane antigen targeting","volume":"30","author":"Li","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2025.112946","article-title":"Exploring the chemistry of H2DEDPA derivatives for [nat\/68Ga]Ga3+ complexation","volume":"271","author":"Torralba-Maldonado","year":"2025","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0270","doi-asserted-by":"crossref","DOI":"10.1021\/ja4049493","article-title":"H4octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy","volume":"135","author":"Price","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0275","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1021\/acs.inorgchem.1c00152","article-title":"Chemical promiscuity of non-macrocyclic multidentate chelating ligands for radiometal ions: H4neunpa-NH2 vs H4noneunpa","volume":"60","author":"Wharton","year":"2021","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0280","doi-asserted-by":"crossref","first-page":"12575","DOI":"10.1021\/ic302225z","article-title":"H2azapa: a versatile acyclic multifunctional chelator for 67Ga, 64Cu, 111In, and 177Lu","volume":"51","author":"Bailey","year":"2012","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0285","doi-asserted-by":"crossref","first-page":"11748","DOI":"10.1039\/D4SC02851A","article-title":"A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements","volume":"15","author":"Wood","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0290","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.7150\/thno.75336","article-title":"3p-C-NETA: a versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals","volume":"12","author":"Ahenkorah","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2023.112267","article-title":"Design and synthesis of a new bifunctional chelating agent: application for Al 18F\/177Lu complexation","volume":"246","author":"Laur\u00e8ne","year":"2023","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0300","doi-asserted-by":"crossref","first-page":"26234","DOI":"10.1021\/acs.jmedchem.5c02286","article-title":"Evaluation of bifunctional, PSMA-targeted triazamacrocycle-picolinates compatible with the 18F\/44Sc\/177Lu isotope triad","volume":"68","author":"Glaser","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0305","doi-asserted-by":"crossref","DOI":"10.1021\/acs.bioconjchem.6c00056","article-title":"Linker chemistry in radiopharmaceutical design","author":"Stoddard","year":"2026","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0310","doi-asserted-by":"crossref","first-page":"25981","DOI":"10.1021\/acs.jmedchem.5c01873","article-title":"Linker-driven breakthrough: design of a novel linker for enhanced theranostic performance of FAPI trimer","volume":"68","author":"Cheng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0315","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.6c00256","article-title":"Linker optimization in Lu-177 labeled \u03b1v\u03b26-integrin binding peptide trimers for targeted radionuclide therapy of cancer","author":"Nguyen","year":"2026","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0320","doi-asserted-by":"crossref","first-page":"20451","DOI":"10.1021\/acsomega.5c11686","article-title":"Chelator conjugation chemistry matters: squaramide linker enhances tumor contrast in 68Ga-labeled anti-CEA nanobody tracer","volume":"11","author":"Sali\u00ebn","year":"2026","journal-title":"ACS Omega"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0325","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1021\/acs.bioconjchem.3c00007","article-title":"A systematic investigation into the influence of net charge on the biological distribution of radiometalated peptides using [68Ga]Ga-DOTA-TATE derivatives","volume":"34","author":"Raheem","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0330","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13550-025-01301-y","article-title":"A preclinical study on the influence of linkers in [68Ga]Ga-NOTA-X-RM26 radiotracers for PET imaging of GRPR expression","volume":"15","author":"Olaniran H\u00e5kansson","year":"2025","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0335","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.3390\/molecules27154959","article-title":"Application of cleavable linkers to improve therapeutic index of radioligand therapies","volume":"27","author":"Lau","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0340","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00259-023-06584-8","article-title":"First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [68Ga]Ga-HER2 affibody","volume":"51","author":"Zhang","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0345","first-page":"2876","article-title":"Design of cleavable linkers for antibody drug conjugates and evaluation of stability using radioimmunoconjugates","volume":"63","author":"Dominguez-Garcia","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0350","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1021\/acsbiomedchemau.5c00224","article-title":"Is thiourea the weak link? An investigation of the in vitro and in vivo destabilization of [203Pb]- and [212Pb]Pb2+ thiourea-based bioconjugates","volume":"6","author":"McNeil","year":"2026","journal-title":"ACS Bio. Med. Chem. Au."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0355","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1021\/acs.bioconjchem.4c00105","article-title":"Moving beyond isothiocyanates: a look at the stability of conjugation links toward radiolysis in 89Zr-labeled immunoconjugates","volume":"35","author":"Vizier","year":"2024","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0360","first-page":"1238","article-title":"Establishing radiolanthanum chemistry for targeted nuclear medicine applications","volume":"26","author":"Aluicio-Sarduy","year":"2020","journal-title":"Chem. Weinh. Bergstr. Ger."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0365","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1039\/D0CS00384K","article-title":"Radiolabelling of nanomaterials for medical imaging and therapy","volume":"50","author":"Pellico","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0370","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3390\/pharmaceutics17070912","article-title":"Nanoradiopharmaceuticals: design principles, radiolabeling strategies, and biomedicine applications","volume":"17","author":"N\u00fa\u00f1ez-Salinas","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0375","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0380","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fnagi.2018.00314","article-title":"Clinical PET imaging of microglial activation: implications for microglial therapeutics in Alzheimer\u2019s disease","volume":"10","author":"Shen","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0385","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0390","doi-asserted-by":"crossref","DOI":"10.1021\/acs.chemrev.9b00738","article-title":"ImmunoPET: concept, design, and applications","author":"Wei","year":"2020","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0395","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/biom13010164","article-title":"ImmunoPET directed to the brain: a new tool for preclinical and clinical neuroscience","volume":"13","author":"de Lucas","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0400","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3390\/pharmaceutics16070882","article-title":"Zirconium 89 and Copper 64 for ImmunoPET: from antibody bioconjugation and radiolabeling to molecular imaging","volume":"16","author":"Badier","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0405","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1021\/acs.bioconjchem.1c00136","article-title":"State of the art in radiolabeling of antibodies with common and uncommon radiometals for preclinical and clinical immuno-PET","volume":"32","author":"Chomet","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0410","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41181-026-00426-2","article-title":"Increasing the activity output and optimization of automated radiosynthesis [68Ga]Ga-DOTATATE, [68Ga]Ga-Pentixafor, and [68Ga]Ga-FAPI-64 using two [68Ge]Ge\/[68Ga]Ga iThemba generators in series","volume":"11","author":"Alfteimi","year":"2026","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0415","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-022-00180-1","article-title":"Good practices for 68Ga radiopharmaceutical production","volume":"7","author":"Nelson","year":"2022","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0420","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2967\/jnumed.118.217158","article-title":"Fully automated 89Zr labeling and purification of antibodies","volume":"60","author":"Poot","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0425","doi-asserted-by":"crossref","first-page":"12004","DOI":"10.1021\/acs.chemrev.3c00456","article-title":"Theranostic nuclear medicine with Gallium-68, Lutetium-177, Copper-64\/67, Actinium-225, and Lead-212\/203 radionuclides","volume":"123","author":"Morgan","year":"2023","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0430","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1021\/acs.molpharmaceut.5c01023","article-title":"Investigating the theranostic potential of elementally matched [43Sc]Sc-PSMA-617 and [47Sc]Sc-PSMA-617","volume":"23","author":"Cingoranelli","year":"2026","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0435","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.1021\/acs.inorgchem.5c01513","article-title":"Advanced 64Cu\/67Cu-Based theranostics: application of the Copper Chelator TE1PA to a murine model of HER2-Positive gastric cancer","volume":"64","author":"Pineau","year":"2025","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0440","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1053\/j.semnuclmed.2025.09.006","article-title":"Advances in dosimetry and imaging for 203Pb and 212Pb radiotheranostics","volume":"55","author":"Ramonaheng","year":"2025","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0445","article-title":"Preclinical evaluation of MC1R targeting theranostic pair [155Tb]Tb-crown-\u03b1MSH and [161Tb]Tb-crown-\u03b1MSH","volume":"136\u2013137","author":"Wharton","year":"2024","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0450","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: structure, regulation and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0455","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.tips.2009.05.005","article-title":"PET Radiotracers: crossing the blood-brain barrier and surviving metabolism","volume":"30","author":"Pike","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0460","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid \u03b2-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0465","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/jcbfm.2013.160","article-title":"Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier","volume":"33","author":"St-Amour","year":"2013","journal-title":"J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0470","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1007\/s00259-025-07338-4","article-title":"PSMA radioligand uptake correlates with PSMA expression in high-grade glioma and brain metastasis: insights from a prospective PET-MRI guided multiregional biopsy study","volume":"52","author":"Pruis","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0475","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.2967\/jnumed.115.154401","article-title":"TGF-\u03b2 antibody uptake in recurrent high-grade glioma imaged with 89Zr-Fresolimumab PET","volume":"56","author":"den Hollander","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0480","doi-asserted-by":"crossref","first-page":"15384","DOI":"10.1038\/s41598-021-94887-x","article-title":"Positron emission tomography imaging with 89Zr-labeled anti-CD8 cys-diabody reveals CD8+ cell infiltration during oncolytic virus therapy in a glioma murine model","volume":"11","author":"Kasten","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0485","doi-asserted-by":"crossref","first-page":"911","DOI":"10.7150\/thno.89206","article-title":"[89Zr]-CD8 ImmunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical models","volume":"14","author":"Gallegos","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0490","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood\u2013brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105068","article-title":"Potential of PSMA-targeting radioligand therapy for malignant primary and secondary brain tumours using super-selective intra-arterial administration: a single centre, open label, non-randomised prospective imaging study","volume":"102","author":"Pruis","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0500","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00270-019-02262-1","article-title":"Will 177Lu-DOTATATE treatment become more effective in salvage meningioma patients, when boosting somatostatin receptor saturation? A promising case on intra-arterial administration","volume":"42","author":"Braat","year":"2019","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0505","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11060-025-05266-9","article-title":"Efficacy of Intra-arterial [177Lu]Lu-DOTATATE monotherapy for treatment-refractory meningioma","volume":"176","author":"El Ghalbouni","year":"2025","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0510","article-title":"Radionuclide selection influences imaging outcomes in immuno-PET with a brain-penetrating anti\u2013Amyloid-\u03b2 antibody","author":"van den Broek","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0515","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.7150\/thno.73509","article-title":"Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential","volume":"12","author":"Wuensche","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0520","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s00259-023-06109-3","article-title":"Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-\u00df monoclonal antibody","volume":"50","author":"Stergiou","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0525","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.7150\/thno.97149","article-title":"PET imaging of microglia in Alzheimer\u2019s disease using copper-64 labeled TREM2 antibodies","volume":"14","author":"Shojaei","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0530","article-title":"New prospects for 89Zr-immuno-PET in brain applications \u2013 Alpha-synucleinopathies","volume":"140\u2013141","author":"Wuensche","year":"2025","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0535","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1039\/c3cs60049a","article-title":"Inverse electron demand Diels\u2013Alder (iEDDA)-initiated conjugation: a (high) potential click chemistry scheme","volume":"42","author":"Knall","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0540","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1021\/bc200288d","article-title":"Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels\u2013Alder click chemistry","volume":"22","author":"Zeglis","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/ph15121445","article-title":"Antibody-based in vivo imaging of central nervous system targets\u2014evaluation of a pretargeting approach utilizing a TCO-conjugated brain shuttle antibody and radiolabeled tetrazines","volume":"15","author":"Bredack","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0550","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1021\/acsabm.0c01555","article-title":"Successful application of CuAAC click reaction in constructing 64Cu-labeled antibody conjugates for immuno-PET imaging","volume":"4","author":"Lee","year":"2021","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0555","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1039\/D2CC06850H","article-title":"Pre-targeting amyloid-\u03b2 with antibodies for potential molecular imaging of Alzheimer\u2019s disease","volume":"59","author":"Morgan","year":"2023","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0560","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1021\/acs.bioconjchem.2c00164","article-title":"Pretargeted PET imaging with a TCO-conjugated anti-CD44v6 chimeric mAb U36 and [89Zr]Zr-DFO-PEG5-Tz","volume":"33","author":"Lumen","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0565","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1039\/D4CB00039K","article-title":"[68Ga]Ga-THP-tetrazine for bioorthogonal click radiolabelling: pretargeted PET imaging of liposomal nanomedicines","volume":"5","author":"Mishra","year":"2024","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0570","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1021\/acs.jmedchem.4c02281","article-title":"An 211At-labeled tetrazine for pretargeted therapy","volume":"68","author":"Herth","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0575","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1038\/s41596-021-00540-2","article-title":"Inverse electron demand Diels\u2013Alder click chemistry for pretargeted PET imaging and radioimmunotherapy","volume":"16","author":"Sarrett","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0580","doi-asserted-by":"crossref","first-page":"28316","DOI":"10.1073\/pnas.2009960117","article-title":"Harnessing 64Cu\/67Cu for a theranostic approach to pretargeted radioimmunotherapy","volume":"117","author":"Kein\u00e4nen","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114708","article-title":"Utilizing biorecognition to prime tumors for enhanced nanomedicine delivery of alpha therapies","volume":"392","author":"Fletcher","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0590","doi-asserted-by":"crossref","first-page":"8201","DOI":"10.1021\/acs.jmedchem.7b01108","article-title":"Exploring structural parameters for pretargeting radioligand optimization","volume":"60","author":"Meyer","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0595","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1021\/acschemneuro.5c00476","article-title":"Enhanced positron emission tomography imaging of \u03b2-amyloid through focused ultrasound-mediated gallium-68 radiotracer delivery across the blood-brain barrier","volume":"16","author":"Li","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0600","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.7150\/thno.87168","article-title":"Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction","volume":"13","author":"Chevaleyre","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0605","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejpb.2022.12.006","article-title":"Refining the delivery and therapeutic efficacy of cetuximab using focused ultrasound in a mouse model of glioblastoma: An 89Zr-cetuximab immunoPET study","volume":"182","author":"Porret","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107246","article-title":"TLD: an optimized liposomal doxorubicin formulation with small vesicle size for improved anti-tumor efficacy","volume":"213","author":"Brkic","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114183","article-title":"PET imaging for non-invasive monitoring of 89Zr-Talidox delivery to the brain following focused ultrasound-mediated blood-brain barrier opening","volume":"387","author":"Mishra","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0620","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/pharmaceutics17030345","article-title":"Intra-Arterial Super-Selective Delivery of Yttrium-90 for the treatment of recurrent glioblastoma: in silico proof of concept with feasibility and safety analysis","volume":"17","author":"Paolani","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0625","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1007\/s00259-021-05350-y","article-title":"Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma \u2013 safety and efficacy","volume":"48","author":"Kr\u00f3licki","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0630","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1007\/s00259-025-07527-1","article-title":"Convection-enhanced delivery of [225Ac]Ac-DOTA-SP in recurrent glioblastoma \u2013 tumour uptake","volume":"53","author":"Tulik","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0635","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jconrel.2018.05.039","article-title":"Focused ultrasound-enabled delivery of radiolabeled nanoclusters to the pons","volume":"283","author":"Ye","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0640","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/acsabm.1c01056","article-title":"C\u2013X\u2013C chemokine receptor Type 4-Targeted imaging in glioblastoma multiforme using 64Cu-Radiolabeled ultrasmall gold nanoclusters","volume":"5","author":"Zhang","year":"2022","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0645","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1039\/D1MD00364J","article-title":"Bifunctional chelators for radiorhenium: past, present and future outlook","volume":"13","author":"Melis","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0650","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.3390\/ijms22083868","article-title":"Translating research for the radiotheranostics of nanotargeted 188Re-liposome","volume":"22","author":"Chang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0655","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/neuonc\/nos060","article-title":"Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma","volume":"14","author":"Phillips","year":"2012","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0660","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41467-025-57263-1","article-title":"Convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial","volume":"16","author":"Brenner","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0665","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","article-title":"Glioma","volume":"10","author":"Weller","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0670","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1021\/acs.molpharmaceut.2c00760","article-title":"Pharmacokinetics and biodistribution of 89Zr-Miltuximab and its antibody fragments as Glypican-1 targeting Immuno-PET agents in glioblastoma","volume":"20","author":"Ghosh","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0675","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11307-019-01427-1","article-title":"Preclinical ImmunoPET imaging of glioblastoma-infiltrating myeloid cells using Zirconium-89 labeled anti-CD11b antibody","volume":"22","author":"Nigam","year":"2020","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0680","first-page":"1562","article-title":"Phase I safety and bioimaging trial of KB004 (ifabotuzumab) in patients with glioblastoma","volume":"61","author":"Gan","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0685","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1158\/1078-0432.CCR-21-1412","article-title":"Whole-body PET imaging of T cell response to glioblastoma","volume":"27","author":"Nobashi","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0690","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.2010.12","article-title":"Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-Positive lesions in patients with metastatic breast cancer","volume":"87","author":"Dijkers","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0695","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.124.268931","article-title":"Quantitative [89 Zr]Zr-Trastuzumab PET and diffusion-weighted MRI for characterization of metastatic HER2-Positive breast cancer with PET\/MRI","author":"Mansur","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0700","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2967\/jnumed.117.202010","article-title":"First-in-Human human epidermal growth factor receptor 2\u2013targeted imaging using 89Zr-Pertuzumab PET\/CT: dosimetry and clinical application in patients with breast cancer","volume":"59","author":"Ulaner","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0705","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.123.266392","article-title":"First-in-Human evaluation of site-specifically labeled 89Zr-Pertuzumab in patients with HER2-Positive breast cancer","volume":"65","author":"Yeh","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0710","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00259-019-04358-9","article-title":"Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET\/CT in patients with newly diagnosed metastatic renal cell carcinoma","volume":"46","author":"Verhoeff","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0715","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1007\/s00259-025-07173-7","article-title":"Preclinical and first-in-human evaluation of [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging to assess tumor PD-L1 expression","volume":"52","author":"Chen","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0720","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1007\/s00259-025-07326-8","article-title":"[68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors","volume":"52","author":"Jiang","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0725","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s11060-018-2825-5","article-title":"Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody","volume":"138","author":"Matsuda","year":"2018","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0730","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2967\/jnumed.123.265738","article-title":"PET imaging and protein expression of prostate-specific membrane antigen in glioblastoma: a multicenter inventory study","volume":"64","author":"SAM","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0735","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000002520","article-title":"Differential uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in low-grade versus high-grade gliomas in treatment-naive patients","volume":"44","author":"Verma","year":"2019","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0740","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.3390\/cancers16244148","article-title":"Immune checkpoint inhibitors in glioblastoma IDHwt treatment: a systematic review","volume":"16","author":"Baskaran","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0745","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/neuonc\/noae190","article-title":"Imaging PD-L1 in the brain\u2014Journey from the lab to the clinic","volume":"27","author":"Dar","year":"2025","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0750","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.7150\/thno.79976","article-title":"In vivo imaging of CD8+ T cells in metastatic cancer patients: first clinical experience with simultaneous [89Zr]Zr-Df-IAB22M2C PET\/MRI","volume":"13","author":"Schwenck","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0755","article-title":"Clinical significance of somatostatin receptor (SSTR) 2 in meningioma","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0760","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111624","article-title":"Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice","volume":"9","author":"Soto-Montenegro","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0765","first-page":"1053","article-title":"PET imaging of somatostatin receptors using [68GA]DOTA-d-Phe1-Tyr3-Octreotide: first results in patients with meningiomas","volume":"42","author":"Henze","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0770","doi-asserted-by":"crossref","first-page":"9256","DOI":"10.1038\/s41598-022-13467-9","article-title":"Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [68Ga]-DOTATATE PET\/MRI analysis in patients with meningioma","volume":"12","author":"Kim","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0775","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1021\/mp500343j","article-title":"44Sc: an attractive isotope for peptide-based PET imaging","volume":"11","author":"Hernandez","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0780","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2967\/jnumed.125.269991","article-title":"[44Sc]Sc-CHX-A\u2033-DTPA-RCCB6: A PET tracer for imaging CD70 expression across latency types of Burkitt lymphoma","volume":"66","author":"Li","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0785","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/pharmaceutics17060796","article-title":"Synthesis and in vitro evaluation of a scandium-44 radiolabeled nanobody as a PD-L1 PET imaging probe","volume":"17","author":"Krol","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0790","article-title":"Evaluation of a novel hexadentate 1,2-hydroxypyridinone-based acyclic chelate, HOPO-O6-C4, for 43Sc\/47Sc, 68Ga, and 45Ti radiopharmaceuticals","volume":"128\u2013129","author":"Carbo-Bague","year":"2024","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0795","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1039\/D0DT00437E","article-title":"Coordination chemistry of [Y(pypa)]\u2212 and comparison immuno-PET imaging of [44Sc]Sc- and [86Y]Y-pypa-phenyl-TRC105","volume":"49","author":"Li","year":"2020","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0800","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1021\/acs.inorgchem.9b03347","article-title":"[nat\/44Sc(pypa)]\u2212: thermodynamic stability, radiolabeling, and biodistribution of a prostate-specific-membrane-antigen-targeting conjugate","volume":"59","author":"Li","year":"2020","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0805","doi-asserted-by":"crossref","DOI":"10.1021\/acs.inorgchem.5c05650","article-title":"Coordination of Scandium(III) by an octadentate bispidine ligand and its application to 44\/47Sc radiolabeling","author":"Petitpoisson","year":"2026","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0810","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jconrel.2020.08.047","article-title":"Impact of blood-brain barrier permeabilization induced by ultrasound associated to microbubbles on the brain delivery and kinetics of cetuximab: an immunoPET study using 89Zr-cetuximab","volume":"328","author":"Tran","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0815","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/jnis-2025-023068","article-title":"Superselective intra-arterial cerebral infusion of chemotherapeutics after osmotic blood\u2013brain barrier disruption in newly diagnosed or recurrent glioblastoma: technical insights and clinical outcomes from a single-center experience","volume":"18","author":"Ferreira","year":"2026","journal-title":"J. Neurointerv. Surg."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0820","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1021\/bc500415x","article-title":"Matching the decay half-life with the biological half-life: ImmunoPET imaging with 44Sc-labeled Cetuximab Fab fragment","volume":"25","author":"Chakravarty","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0825","doi-asserted-by":"crossref","first-page":"13835","DOI":"10.1021\/acsomega.5c11942","article-title":"[64Cu]Cu-Labeled \u03b1CD11b diabody as a novel PET tracer for the detection of immunosuppression in glioblastoma","volume":"11","author":"Li","year":"2026","journal-title":"ACS Omega"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0830","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1186\/s12885-019-6368-8","article-title":"Impact of [64Cu][Cu(ATSM)] PET\/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report","volume":"19","author":"Gangemi","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0835","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13550-023-01052-8","article-title":"Assessment of hypoxia and oxidative-related changes in a lung-derived brain metastasis model by [64Cu][Cu(ATSM)] PET and proteomic studies","volume":"13","author":"Fantin","year":"2023","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0840","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm6267","article-title":"PET imaging of TREM1 identifies CNS-infiltrating myeloid cells in a mouse model of multiple sclerosis","volume":"15","author":"Chaney","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0845","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1021\/acsptsci.4c00037","article-title":"Development and preclinical evaluation of a Copper-64-Labeled antibody targeting glycine-alanine dipeptides for PET imaging of C9orf72-associated amyotrophic lateral sclerosis\/frontotemporal dementia","volume":"7","author":"Shojaei","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0850","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.126.272419","article-title":"[68Ga]Ga-DOTA-5G PET\/CT detects brain and bone metastases in a patient with metastatic pancreatic cancer","author":"Foster","year":"2026","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0855","article-title":"Preclinical and first-in-human evaluation of [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging to assess tumor PD-L1 expression","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0860","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-026-07853-y","article-title":"A phase I study to evaluate the dosimetry and safety of [89Zr]Zr-DFO-AP-101, a new antibody-based radiopharmaceutical to detect misfolded SOD1 in amyotrophic lateral sclerosis","author":"Croteau","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0865","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009486","article-title":"EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses","volume":"12","author":"Lertsumitkul","year":"2024","journal-title":"J. Immunother Cancer"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0870","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1470-2045(24)00249-3","article-title":"Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1\/2, first-in-human trial","volume":"25","author":"Tendler","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0875","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0880","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","article-title":"Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets","volume":"8","author":"Gao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0885","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41419-024-07206-3","article-title":"Copper homeostasis and cuproptosis in central nervous system diseases","volume":"15","author":"Zhu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0890","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1039\/b705989b","article-title":"Cu\u2013ATSM: a radiopharmaceutical for the PET imaging of hypoxia","author":"V\u0101vere","year":"2007","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0895","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13550-019-0586-6","article-title":"64Cu-ATSM\/64Cu-Cl2 and their relationship to hypoxia in glioblastoma: a preclinical study","volume":"9","author":"P\u00e9r\u00e8s","year":"2019","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0900","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.nucmedbio.2011.02.016","article-title":"Evaluation of striatal oxidative stress in patients with Parkinson\u2019s disease using [62Cu]ATSM PET","volume":"38","author":"Ikawa","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0905","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3390\/brainsci15080844","article-title":"A targeted radiotheranostic agent for glioblastoma: [64Cu]Cu-NOTA-TP-c(RGDfK)","volume":"15","author":"Mirzaei","year":"2025","journal-title":"Brain Sci."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0910","first-page":"177","article-title":"Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model","volume":"40","author":"Lewis","year":"1999","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0915","first-page":"1155","article-title":"Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential","volume":"38","author":"Fujibayashi","year":"1997","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0920","doi-asserted-by":"crossref","DOI":"10.1007\/s00702-025-03081-0","article-title":"Evaluation of increased oxidative stress in the brain of patients with early Alzheimer\u2019s disease by 64Cu-ATSM PET\/MRI","author":"Huang","year":"2025","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0925","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s41181-025-00383-2","article-title":"Brain-penetrating peptide and antibody radioligands for proof-of-concept PET imaging of fibrin in Alzheimer\u2019s disease","volume":"10","author":"Sehlin","year":"2025","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0930","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0935","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.124.268902","article-title":"177Lu-DOTATATE in combination with PARP inhibitor Olaparib Is feasible in patients with somatostatin-positive tumors: results from the LuPARP Phase I trial","author":"Hallqvist","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0940","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1021\/acs.molpharmaceut.5c01203","article-title":"Development of a CD9-Targeted radiopharmaceutical for imaging and radionuclide therapy in CD9-Positive Glioma","volume":"22","author":"Fan","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0945","first-page":"262","article-title":"Phase 1 study of [177Lu]Lu-NeoB in patients with advanced solid tumors overexpressing gastrin-releasing peptide receptor: preliminary safety and dosimetry results","volume":"67","author":"Mittra","year":"2026","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0950","article-title":"Convection-enhanced delivery of [177Lu]Lu-labeled gold nanoparticles combined with anti-PD1 checkpoint immunotherapy improves the survival of immunocompetent C57BL\/6J mice with orthotopic GL261 murine glioma tumors","volume":"140\u2013141","author":"Georgiou","year":"2025","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0955","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1007\/s00259-019-04354-z","article-title":"Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0960","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/neuonc\/noz169","article-title":"VCAM-1 targeted alpha-particle therapy for early brain metastases","volume":"22","author":"Corroyer-Dulmont","year":"2020","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0965","article-title":"[177Lu]Lu-DOTATATE for recurrent meningioma (LUMEN-1, EORTC-2334-BTG): study protocol for a randomized Phase II trial","author":"Albert","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0970","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","article-title":"Evaluation of the SSTR2-targeted radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as imaging biomarker in patients with intracranial meningioma","volume":"30","author":"Kurz","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0975","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00259-022-06044-9","article-title":"Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma","volume":"50","author":"Minczeles","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0980","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/RLU.0000000000005845","article-title":"Long-term efficacy, survival, and toxicity of peptide receptor radionuclide therapy in patients with refractory meningioma","volume":"50","author":"Zhang","year":"2025","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0985","doi-asserted-by":"crossref","first-page":"232","DOI":"10.7150\/thno.62851","article-title":"Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs","volume":"12","author":"Miller","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0990","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2967\/jnumed.122.264979","article-title":"Evaluation of candidate theranostics for227 Th\/89 Zr paired radioimmunotherapy of lymphoma","volume":"64","author":"Abou","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb0995","doi-asserted-by":"crossref","first-page":"20721","DOI":"10.1021\/acs.inorgchem.3c02164","article-title":"Macrocyclic 1,2-Hydroxypyridinone-Based chelators as potential ligands for Thorium-227 and Zirconium-89 radiopharmaceuticals","volume":"62","author":"Woods","year":"2023","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1000","article-title":"Matched pair suitability of 89Zr and 177Lu-labeled L804-LLP2A theranostics for targeting VLA-4 in melanoma","volume":"152\u2013153","author":"Fong","year":"2026","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1005","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2967\/jnumed.124.267667","article-title":"Single chelator\u2013minibody theranostic agents for 89Zr PET imaging and 177Lu radiopharmaceutical therapy of PSMA-expressing prostate cancer","volume":"65","author":"Ho","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1010","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1021\/bc800299f","article-title":"Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges","volume":"20","author":"Nayak","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1015","first-page":"71","article-title":"Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma","author":"Foster","year":"2021","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13550-024-01084-8","article-title":"Evaluation of the theranostic potential of [64Cu]CuCl2 in glioblastoma spheroids","volume":"14","author":"Pinto","year":"2024","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1025","article-title":"Phase I study of 64Cu-ATSM therapy in malignant brain tumors: safety, pharmacokinetics, and preliminary outcomes","volume":"66","author":"Ito","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11307-022-01769-3","article-title":"Diagnostic and dosimetry features of [64Cu]CuCl2 in high-grade paediatric infiltrative gliomas","volume":"25","author":"Fiz","year":"2023","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1035","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.122.264586","article-title":"64Cu treatment planning and 67Cu therapy with radiolabeled [64Cu\/67Cu]MeCOSar-Octreotate in subjects with unresectable multifocal meningioma: initial results for human imaging, safety, biodistribution, and radiation dosimetry","volume":"64","author":"Bailey","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1040","article-title":"Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy","volume":"146\u2013147","author":"Cruz-Nova","year":"2025","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1045","series-title":"Implementing Ac-225 Labelled Radiopharmaceuticals: Practical Considerations and (pre-)Clinical Perspectives","author":"Hooijman","year":"2026"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1050","doi-asserted-by":"crossref","first-page":"17220","DOI":"10.1021\/acs.inorgchem.5c02195","article-title":"Coordination confinement on the decay chains of typical medical \u03b1-radionuclides","volume":"64","author":"Qiu","year":"2025","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1055","doi-asserted-by":"crossref","first-page":"7592","DOI":"10.1021\/acs.inorgchem.5c04349","article-title":"Macrocyclic and hydroxamate ligands for 225Ac radiopharmaceuticals: evaluating SSTR2-targeting potential","volume":"65","author":"Tsushima","year":"2026","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1060","series-title":"Comparable Daughter Radionuclide Redistribution with Superior Tumor Absorbed Dose of the SSTR2 Antagonist [225Ac]Ac-SSO110 Versus [225Ac]Ac- DOTA-TATE. 2026.03.16.711095","author":"Desai","year":"2026"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1065","first-page":"P129","article-title":"225Ac-DOTATATE dosimetry results from Part 1 of the ACTION-1 trial","volume":"64","author":"Sgouros","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1070","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1007\/s00259-024-06811-w","article-title":"Examination of the PET in vivo generator 134Ce as a theranostic match for 225Ac","volume":"51","author":"Bauer","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1075","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.7150\/thno.106081","article-title":"Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment","volume":"15","author":"Roncali","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1080","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s11523-024-01071-y","article-title":"Targeted alpha therapy for glioblastoma: review on in vitro, in vivo and clinical trials","volume":"19","author":"Sabri","year":"2024","journal-title":"Target. Oncol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1085","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3390\/cancers12041017","article-title":"Preclinical targeted \u03b1- and \u03b2\u2212-Radionuclide therapy in HER2-Positive brain metastasis using camelid single-domain antibodies","volume":"12","author":"Puttemans","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1090","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.2967\/jnumed.123.266894","article-title":"Radiolabeling and preclinical evaluation of therapeutic efficacy of225 Ac-ch806 in glioblastoma and colorectal cancer xenograft models","volume":"65","author":"Wichmann","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s41181-025-00362-7","article-title":"212Pb in targeted radionuclide therapy: a review","volume":"10","author":"Scaffidi-Muta","year":"2025","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1100","doi-asserted-by":"crossref","first-page":"v144","DOI":"10.1093\/neuonc\/noaf201.0571","article-title":"CTNI-76. Unlocking the power of LDL- receptors in glioblastoma","volume":"27","author":"Delpassand","year":"2025","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1105","first-page":"2882","article-title":"Novel radiotracer targeting LDLR-overexpressing glioblastoma and pancreatic ductal adenocarcinoma \u2013 preclinical and dosimetry studies","volume":"63","author":"Tworowska","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1110","first-page":"P1491","article-title":"212Pb-DOTAM-peptide targeting LDLR-receptors in glioblastoma and pancreatic ductal adenocarcinoma","volume":"64","author":"Tworowska","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1115","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/pharmaceutics16060738","article-title":"The different strategies for the radiolabeling of [211At]-Astatinated radiopharmaceuticals","volume":"16","author":"Gao","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116919","article-title":"211At radiolabeled APBA-FAPI for enhanced targeted-alpha therapy of glioma","volume":"279","author":"Ye","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1125","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1021\/acs.molpharmaceut.5c00989","article-title":"Multivalent 211At-Radiolabeled fibroblast activation protein inhibitors for targeted alpha-therapy of glioma","volume":"22","author":"Ye","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1130","doi-asserted-by":"crossref","first-page":"18248","DOI":"10.1038\/s41598-025-03356-2","article-title":"Locoregional radionuclide therapy of glioblastoma with [211At]At-PDA-FAPI","volume":"15","author":"Ma","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnumed.107.046938","article-title":"Clinical experience with \u03b1-Particle\u2013Emitting 211At: treatment of recurrent brain tumor patients with 211At-Labeled chimeric antitenascin monoclonal antibody 81C6","volume":"49","author":"Zalutsky","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105202","article-title":"Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice","volume":"105","author":"Roncali","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1145","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ijrobp.2021.06.012","article-title":"Modulation of neuroinflammation by low-dose radiation therapy in an animal model of Alzheimer\u2019s disease","volume":"111","author":"Yang","year":"2021","journal-title":"Int. J. Radiat Oncol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijrobp.2023.03.044","article-title":"Low-Dose whole brain radiation therapy for Alzheimer\u2019s dementia: results from a pilot trial in humans","volume":"117","author":"Rogers","year":"2023","journal-title":"Int. J. Radiat Oncol."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1155","first-page":"1467","article-title":"Development of a 213Bi-labeled pyridyl benzofuran for targeted \u03b1-therapy of Amyloid-\u03b2 aggregates","volume":"65","author":"Bender","year":"2024","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"10.1016\/j.jinorgbio.2026.113397_bb1160","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s12149-025-02095-8","article-title":"Feasibility of targeted alpha therapy for Alzheimer\u2019s disease using 211At-labeled agent targeting amyloid-\u03b2 aggregates","volume":"39","author":"Kashiyama","year":"2025","journal-title":"Ann. Nucl. Med."}],"container-title":["Journal of Inorganic Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0162013426001868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0162013426001868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:51:16Z","timestamp":1785073876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0162013426001868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":232,"alternative-id":["S0162013426001868"],"URL":"https:\/\/doi.org\/10.1016\/j.jinorgbio.2026.113397","relation":{},"ISSN":["0162-0134"],"issn-type":[{"value":"0162-0134","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From PET to targeted radionuclide therapy in the Brain: The emerging role of radiometal-based platforms","name":"articletitle","label":"Article Title"},{"value":"Journal of Inorganic Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinorgbio.2026.113397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113397"}}